Oxymetholone: III. Evaluation in the p53+/- Transgenic Mouse Model

Toxicologic Pathology

Volumn 27, Issue 5, 1999, Pages 513-518

  Stoll, Raymond E ^a   Holden, Henry E ^a   Barthel, Curt H ^a   Blanchard, Kerry T ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

bladder tumors; carcinogenicity; Oxymetholone; p cresidine; p53+ ; transgenic

Indexed keywords

OXYMETHOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGEN TESTING; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENETIC TOXICOLOGY; GENOTOXICITY; HETEROZYGOSITY; MALE; MORTALITY; MOUSE; MUTAGENIC ACTIVITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANABOLIC AGENTS; ANIMALS; BODY WEIGHT; CARCINOGENICITY TESTS; CARCINOGENS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENES, P53; HETEROZYGOTE; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; OXYMETHOLONE; PAPILLOMA; PRECANCEROUS CONDITIONS; SURVIVAL ANALYSIS; TESTIS;

ANIMALIA; MUS MUSCULUS; RODENTIA; ZEA MAYS;

EID: 0032829039     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700503     Document Type: Article

References (12)

1. Bootman J. (1996). Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organized by the U.S. National Toxicology Program. Environ. Mol. Mutagen. 19: 237-243.
2. Donehower L., Harvey M., Slagle B., McArthur M., Montgomery C., Butel J., and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221.
3. Holden HE, Stoll RE, and Blanchard KT (1999). Oxymetholone: II. Evaluation in the Tg.AC transgenic mouse model for detection of carcinogens. Toxicol. Pathol. 27: 507-512 (this issue).
4. Holden HE, Studwell D., and Majeska JB (1999). Oxymetholone: I. Evaluation in a comprehensive battery of genetic toxicology and in vitro transformation assays. Toxicol. Pathol. 27: 501-506 (this issue).
5. Kastan M., Zhan Q., el-Deiry W., Carrier F., Jacks T., Walsh W., Plunkett B., Vogelstein B., and Fornace A. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
6. Lane D. (1992). p53, guardian of the genome. Nature 358: 15-16.
7. Mahler J., Flagler N., Malarkey D., Mann P., Haseman J., and Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol. Pathol. 26: 501-511.
8. National Cancer Institute (1979). Bioassay of p-Cresidine for Possible Carcinogenicity. Carcinogenesis Technical Report Series No. 142, National Cancer Institute, Bethesda, Maryland.
9. National Toxicology Program (1998). Management Status Report, April. Department of Health and Human Services, National Institutes of Health, National Institute for Envionmental Health Sciences, Research Triangle Park, North Carolina, p. 13.
10. Rosenkrantz H. and McCoy E. (1981). meta-Cresidine, para-Cresidine. Contract No. I-CP 65855. Division of Cancer Causes and Prevention, National Cancer Institute, Bethesda, Maryland, pp. 1-10, 871-879.
11. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950.
12. Tennant RW, Spalding JW, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and non-carcinogens. Mutat. Res. 365: 119-127.